These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
101 related items for PubMed ID: 2906066
21. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):21S-26S. PubMed ID: 3220967 [Abstract] [Full Text] [Related]
22. Diazepam-induced changes in tardive dyskinesia: suggestions for a new conceptual model. Singh MM, Becker RE, Pitman RK, Nasrallah HA, Lal H, Dufresne RL, Weber SS, McCalley-Whitters M. Biol Psychiatry; 1982 Jun; 17(6):729-42. PubMed ID: 6125219 [Abstract] [Full Text] [Related]
23. Pharmacologic relationship of antisaccade and dyskinesia in schizophrenic patients. Cassady SL, Thaker GK, Tamminga CA. Psychopharmacol Bull; 1993 Jun; 29(2):235-40. PubMed ID: 8290671 [Abstract] [Full Text] [Related]
25. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Fu Y, Fan CH, Deng HH, Hu SH, Lv DP, Li LH, Wang JJ, Lu XQ. Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169 [Abstract] [Full Text] [Related]
27. Serum interferon in schizophrenia. Rimón R, Ahokas A, Hintikka J, Heikkilä L. Ann Clin Res; 1985 Mar; 17(4):139-40. PubMed ID: 4073801 [Abstract] [Full Text] [Related]
28. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, Dorevitch A, Yakir A, Greenberg D, Lerner A, Lerer B. Mol Psychiatry; 2001 Mar; 6(2):225-9. PubMed ID: 11317227 [Abstract] [Full Text] [Related]
29. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients. Kang SG, Choi JE, An H, Lim SW, Lee HJ, Han C, Kim YK, Kim SH, Cho SN, Lee MS, Joe SH, Jung IK, Kim L. Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug 01; 32(6):1545-8. PubMed ID: 18602732 [Abstract] [Full Text] [Related]
30. Tardive dyskinesia in outpatient schizophrenics treated with depot phenothiazines. Williams R, Naya A, Dalby JT. J Clin Psychopharmacol; 1986 Oct 01; 6(5):318-9. PubMed ID: 3771819 [No Abstract] [Full Text] [Related]
31. Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia. Monteleone P, Maj M, Ariano MG, Iovino M, Fiorenza L, Steardo L. Psychopharmacology (Berl); 1988 Oct 01; 96(2):223-6. PubMed ID: 3148149 [Abstract] [Full Text] [Related]
32. Serum vitamin B6 in schizophrenic and schizoaffective patients with and without tardive dyskinesia. Miodownik C, Lerner V, Cohen H, Kotler M. Clin Neuropharmacol; 2000 Oct 01; 23(4):212-5. PubMed ID: 11020126 [Abstract] [Full Text] [Related]
33. Relationship of butaperazine blood levels to plasma prolactin in chronic schizophrenic patients. Smith RC, Tamminga CA, Crayton JW, Dekirmenjian H, Davis JM. Psychopharmacology (Berl); 1979 Oct 01; 66(1):29-33. PubMed ID: 44374 [Abstract] [Full Text] [Related]
34. The plasma phenylalanine/large neutral amino acid ratio: a risk factor for tardive dyskinesia. Richardson MA, Suckow R, Whittaker R, Boggiano W, Sziraki I, Kushner H, Perumal A. Psychopharmacol Bull; 1989 Oct 01; 25(1):47-51. PubMed ID: 2772116 [No Abstract] [Full Text] [Related]
35. Serum concentration of depot neuroleptics in tardive dyskinesia. Fairbairn AF, Rowell FJ, Hui SM, Hassanyeh F, Robinson AJ, Eccleston D. Br J Psychiatry; 1983 Jun 01; 142():579-83. PubMed ID: 6882980 [Abstract] [Full Text] [Related]
36. Relationship of symptomatology of schizophrenia and tardive dyskinesia. Perenyi A, Norman T, Burrows GD. Eur Neuropsychopharmacol; 1992 Mar 01; 2(1):51-5. PubMed ID: 1638174 [Abstract] [Full Text] [Related]